Public Release:  Gender-biased heart damage

Rockefeller University Press

IMAGE

IMAGE: Androgen treatment repaired (arrows) damaged vessels in castrated mice. view more

Credit: Sieveking, D.P., et al. 2010. J. Exp. Med. doi:10.1084/jem.20091924

A man's male hormones may ward off heart damage by helping vessels around the heart regenerate, suggest Australian researchers in a report posted January 13 in the Journal of Experimental Medicine (www.jem.org).

While studies have shown that estrogen helps blood vessels regenerate, both in the uterus after menstruation and around the heart after wear and tear, little is known about whether or not men make up for a lack of the female hormone. Some researchers have theorized that this disparity accounts for why men tend to suffer worse heart attacks more often and earlier in life than women. However, Sieveking and colleagues find that this trend may be due to a drop in androgens, a collective term for male hormones, as men age.

Cells derived from the umbilical cord of a human male fetus responded to androgens by moving and multiplying--activities associated with new vessel growth. Furthermore, castrated mice, which produced fewer androgens, fared poorly after the researchers inflicted vessel damage intended to resemble injuries that occur during a heart attack or a stroke. And treating the castrated mice with androgens hastened their recovery.

Therefore, the authors suggest that androgen replacement therapy might one day be used to treat men at risk for heart disease. The therapy currently receives attention for possibly inducing other rejuvenating benefits, such as increased energy and muscle mass. However, it's been approached with caution as androgens have been shown to assist in tumor growth in prostate cancer--perhaps by stimulating tumor-promoting vessel growth.

###

About The Journal of Experimental Medicine

The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit www.jem.org.

Sieveking, D.P., et al. 2010. J. Exp. Med. doi:10.1084/jem.20091924

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.